Literature DB >> 14502650

Neuropathological spectrum of synucleinopathies.

Kurt A Jellinger1.   

Abstract

Synucleinopathies comprise a diverse group of neurodegenerative proteinopathies that share common pathological lesions composed of aggregates of conformational and posttranslational modifications of alpha-synuclein in selected populations of neurons and glia. Abnormal filamentous aggregates of misfolded alpha-synuclein protein are the major components of Lewy bodies, dystrophic (Lewy) neurites, and the Papp-Lantos filaments in oligodendroglia and neurons in multiple system atrophy linked to degeneration of affected brain regions. The synucleinopathies include (1) Lewy body disorders and dementia with Lewy bodies, (2) multiple system atrophy (MSA), and (3) Hallervorden-Spatz disease. (1) The pathological diagnosis of Lewy body disorders and dementia with Lewy bodies is established by validated consensus criteria based on semiquantitative assessment of subcortical and cortical Lewy bodies as their common hallmarks. They are accompanied by subcortical multisystem degeneration with neuronal loss and gliosis with or without Alzheimer pathologic state. Lewy bodies also occur in numerous other disorders, including pure autonomic failure, neuroaxonal dystrophies, and various amyloidoses and tauopathies. (2) Multiple system atrophy, a sporadic, adult-onset degenerative movement disorder of unknown cause, is characterized by alpha-synuclein-positive glial cytoplasmic and rare neuronal inclusions throughout the central nervous system associated with striatonigral degeneration, olivopontocerebellar atrophy, and involvement of medullar and spinal autonomic nuclei. (3) In neurodegeneration with brain iron accumulation type I, or Hallervorden-Spatz disease, alpha-synuclein is present in axonal spheroids and glial and neuronal inclusions. While the identity of the major components of Lewy bodies suggests that a pathway leading from normal soluble to abnormal misfolded filamentous proteins is central for their pathogenesis, regardless of the primary disorder, there are conformational differences in alpha-synuclein between neuronal and glial aggregates, showing nonuniform mapping for its epitopes. Despite several cellular and transgenic models, it is not clear whether inclusion body formation is an adaptive/neuroprotective or a pathogenic reaction/process generated in response to different, mostly undetermined, functional triggers linked to neurodegeneration. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502650     DOI: 10.1002/mds.10557

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  85 in total

1.  A soluble α-synuclein construct forms a dynamic tetramer.

Authors:  Wei Wang; Iva Perovic; Johnathan Chittuluru; Alice Kaganovich; Linh T T Nguyen; Jingling Liao; Jared R Auclair; Derrick Johnson; Anuradha Landeru; Alana K Simorellis; Shulin Ju; Mark R Cookson; Francisco J Asturias; Jeffrey N Agar; Brian N Webb; Chulhee Kang; Dagmar Ringe; Gregory A Petsko; Thomas C Pochapsky; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems.

Authors:  Allison W Willis; Bradley A Evanoff; Min Lian; Aiden Galarza; Andrew Wegrzyn; Mario Schootman; Brad A Racette
Journal:  Am J Epidemiol       Date:  2010-10-19       Impact factor: 4.897

Review 3.  Amyloidogenesis of natively unfolded proteins.

Authors:  Vladimir N Uversky
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

Review 4.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

5.  Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients.

Authors:  Liancai Mu; Jingming Chen; Stanislaw Sobotka; Themba Nyirenda; Brian Benson; Fiona Gupta; Ira Sanders; Charles H Adler; John N Caviness; Holly A Shill; Marwan Sabbagh; Johan E Samanta; Lucia I Sue; Thomas G Beach
Journal:  Dysphagia       Date:  2015-06-04       Impact factor: 3.438

Review 6.  Structural variants in SNCA gene and the implication to synucleinopathies.

Authors:  Ornit Chiba-Falek
Journal:  Curr Opin Genet Dev       Date:  2017-03-02       Impact factor: 5.578

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

8.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Authors:  Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

9.  Urban air pollution: influences on olfactory function and pathology in exposed children and young adults.

Authors:  Lilian Calderón-Garcidueñas; Maricela Franco-Lira; Carlos Henríquez-Roldán; Norma Osnaya; Angelica González-Maciel; Rafael Reynoso-Robles; Rafael Villarreal-Calderon; Lou Herritt; Diane Brooks; Sheyla Keefe; Juan Palacios-Moreno; Rodolfo Villarreal-Calderon; Ricardo Torres-Jardón; Humberto Medina-Cortina; Ricardo Delgado-Chávez; Mario Aiello-Mora; Robert R Maronpot; Richard L Doty
Journal:  Exp Toxicol Pathol       Date:  2009-03-17

10.  Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.

Authors:  Sylvia Stemberger; Werner Poewe; Gregor K Wenning; Nadia Stefanova
Journal:  Exp Neurol       Date:  2010-05-21       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.